Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jennifer M Kwon

Showing results (31-40 of 47) with videos related to

Pageof 5
Sort By:
International Journal of Neonatal Screening|April 23, 2024
Long-Term Follow-Up Cares and Check Initiative: A Program to Advance Long-Term Follow-Up in Newborns Identified with a Disease through Newborn ScreeningMei Lietsch, Kee Chan, Jennifer Taylor, et al.
American Journal of Human Genetics|January 25, 2003
Mutations in the small GTP-ase late endosomal protein RAB7 cause Charcot-Marie-Tooth type 2B neuropathyKristien Verhoeven, Peter De Jonghe, Katrien Coen, et al.
Annals of Clinical and Translational Neurology|May 14, 2022
An expanded access program of risdiplam for patients with Type 1 or 2 spinal muscular atrophyJennifer M Kwon, Kapil Arya, Nancy Kuntz, et al.
Journal of Inherited Metabolic Disease|December 15, 2011
Females experience a more severe disease course in Batten diseaseJennifer Cialone, Heather Adams, Erika F Augustine, et al.
World Journal of Pediatrics : WJP|March 25, 2019
Progress in treatment and newborn screening for Duchenne muscular dystrophy and spinal muscular atrophyQing Ke, Zheng-Yan Zhao, Jerry R Mendell, et al.
Molecular Therapy. Nucleic Acids|March 10, 2025
Potential ASO-based personalized treatment for Charcot-Marie-Tooth disease type 2SSandra Smieszek, Bartlomiej Przychodzen, Christina Tyner, et al.
Journal of Child Neurology|October 6, 2010
Clinical seizures in neonatal hypoxic-ischemic encephalopathy have no independent impact on neurodevelopmental outcome: secondary analyses of data from the neonatal research network hypothermia trialJennifer M Kwon, Ronnie Guillet, Seetha Shankaran, et al.
Nature Medicine|December 8, 2025
Intrathecal onasemnogene abeparvovec for treatment-experienced patients with spinal muscular atrophy: a phase 3b, open-label trialJennifer M Kwon, Francina Munell, Laure Le Goff, et al.
Nature Medicine|January 28, 2026
Author Correction: Intrathecal onasemnogene abeparvovec for treatment-experienced patients with spinal muscular atrophy: a phase 3b, open-label trialJennifer M Kwon, Francina Munell, Laure Le Goff, et al.
Human Molecular Genetics|July 2, 2004
Evidence of common and specific genetic effects: association of the muscarinic acetylcholine receptor M2 (CHRM2) gene with alcohol dependence and major depressive syndromeJen C Wang, Anthony L Hinrichs, Heather Stock, et al.
Pageof 5

Showing results (31-40 of 47) with videos related to

Sort By:
Pageof 5
International Journal of Neonatal Screening|April 23, 2024
Long-Term Follow-Up Cares and Check Initiative: A Program to Advance Long-Term Follow-Up in Newborns Identified with a Disease through Newborn ScreeningMei Lietsch, Kee Chan, Jennifer Taylor, et al.
American Journal of Human Genetics|January 25, 2003
Mutations in the small GTP-ase late endosomal protein RAB7 cause Charcot-Marie-Tooth type 2B neuropathyKristien Verhoeven, Peter De Jonghe, Katrien Coen, et al.
Annals of Clinical and Translational Neurology|May 14, 2022
An expanded access program of risdiplam for patients with Type 1 or 2 spinal muscular atrophyJennifer M Kwon, Kapil Arya, Nancy Kuntz, et al.
Journal of Inherited Metabolic Disease|December 15, 2011
Females experience a more severe disease course in Batten diseaseJennifer Cialone, Heather Adams, Erika F Augustine, et al.
World Journal of Pediatrics : WJP|March 25, 2019
Progress in treatment and newborn screening for Duchenne muscular dystrophy and spinal muscular atrophyQing Ke, Zheng-Yan Zhao, Jerry R Mendell, et al.
Molecular Therapy. Nucleic Acids|March 10, 2025
Potential ASO-based personalized treatment for Charcot-Marie-Tooth disease type 2SSandra Smieszek, Bartlomiej Przychodzen, Christina Tyner, et al.
Journal of Child Neurology|October 6, 2010
Clinical seizures in neonatal hypoxic-ischemic encephalopathy have no independent impact on neurodevelopmental outcome: secondary analyses of data from the neonatal research network hypothermia trialJennifer M Kwon, Ronnie Guillet, Seetha Shankaran, et al.
Nature Medicine|December 8, 2025
Intrathecal onasemnogene abeparvovec for treatment-experienced patients with spinal muscular atrophy: a phase 3b, open-label trialJennifer M Kwon, Francina Munell, Laure Le Goff, et al.
Nature Medicine|January 28, 2026
Author Correction: Intrathecal onasemnogene abeparvovec for treatment-experienced patients with spinal muscular atrophy: a phase 3b, open-label trialJennifer M Kwon, Francina Munell, Laure Le Goff, et al.
Human Molecular Genetics|July 2, 2004
Evidence of common and specific genetic effects: association of the muscarinic acetylcholine receptor M2 (CHRM2) gene with alcohol dependence and major depressive syndromeJen C Wang, Anthony L Hinrichs, Heather Stock, et al.
Pageof 5